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RESEARCH ARTICLE
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Abstract
Introduction
Hydrocephalus is a complex neurological disorder with a pervasive impact on the central
nervous system. Previous work has demonstrated derangements in the biochemical profile
of cerebrospinal fluid (CSF) in hydrocephalus, particularly in infants and children, in whom
neurodevelopment is progressing in parallel with concomitant neurological injury. The objec-
tive of this study was to examine the CSF of children with congenital hydrocephalus (CHC)
to gain insight into the pathophysiology of hydrocephalus and identify candidate biomarkers
of CHC with potential diagnostic and therapeutic value.
Methods
CSF levels of amyloid precursor protein (APP) and derivative isoforms (sAPPα, sAPPβ,
Aβ42), tau, phosphorylated tau (pTau), L1CAM, NCAM-1, aquaporin 4 (AQP4), and total
protein (TP) were measured by ELISA in 20 children with CHC. Two comparative groups
were included: age-matched controls and children with other neurological diseases. Demo-
graphic parameters, ventricular frontal-occipital horn ratio, associated brain malformations,
genetic alterations, and surgical treatments were recorded. Logistic regression analysis and
receiver operating characteristic curves were used to examine the association of each CSF
protein with CHC.
Results
CSF levels of APP, sAPPα, sAPPβ, Aβ42, tau, pTau, L1CAM, and NCAM-1 but not AQP4 or
TP were increased in untreated CHC. CSF TP and normalized L1CAM levels were associ-
ated with FOR in CHC subjects, while normalized CSF tau levels were associated with FOR
in control subjects. Predictive ability for CHC was strongest for sAPPα, especially in subjects
12 months of age (p<0.0001 and AUC = 0.99), followed by normalized sAPPβ (p = 0.0001,
PLOS ONE | DOI:10.1371/journal.pone.0172353 February 17, 2017 1 / 20
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Limbrick DD, Jr., Baksh B, Morgan CD,
Habiyaremye G, McAllister JP, II, Inder TE, et al.
(2017) Cerebrospinal fluid biomarkers of infantile
congenital hydrocephalus. PLoS ONE 12(2):
e0172353. doi:10.1371/journal.pone.0172353
Editor: Yoko Hoshi, Medical Photonics Research
Center, Hamamatsu University School of Medicine,
JAPAN
Received: September 8, 2016
Accepted: February 4, 2017
Published: February 17, 2017
Copyright: © 2017 Limbrick et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This project was supported by a career
development award to D.D.L. (NIH/NINDS K23
NS075151), the Washington University Intellectual
and Developmental Disabilities Research Center
(NIH/NICHD P30 HD0627171), and a grant from
the Children’s Surgical Sciences Institute, St. Louis
Children’s Hospital (D.L.). J.P.M received support
from a Hydrocephalus Association Innovator
AUC = 0.95), tau, APP, and L1CAM. Among subjects12 months, a normalized CSF
sAPPα cut-point of 0.41 provided the best prediction of CHC (odds ratio = 528, sensitivity =
0.94, specificity = 0.97); these infants were 32 times more likely to have CHC.
Conclusions
CSF proteins such as sAPPα and related proteins hold promise as biomarkers of CHC in
infants and young children, and provide insight into the pathophysiology of CHC during this
critical period in neurodevelopment.
Introduction
Hydrocephalus is a debilitating neurological condition affecting approximately 1 in every 1000
children born in the United States [1]. While traditionally viewed as an imbalance in the produc-
tion and absorption of cerebrospinal fluid (CSF), hydrocephalus is now recognized as a complex
disease with a pervasive impact on the central nervous system [2, 3]. Hydrocephalus results in
structural deformation, axonal stretch, ischemia, inflammation, and impaired precursor cell pro-
liferation/migration among other pathophysiological processes [1, 4–6]. Extensive derangements
in the biochemical profile of CSF are thus expected in the setting of hydrocephalus, particularly
in infants and children, in whom neurodevelopment is progressing in parallel with concomitant
neurological injury. Consequently, experimental analysis of CSF may provide unique insights
into the pathophysiology of hydrocephalus and also offer the opportunity to identify candidate
biomarkers of hydrocephalus with potential diagnostic and therapeutic value.
Our previous work in post-hemorrhagic hydrocephalus (PHH) of prematurity has shown alter-
ations in CSF levels of amyloid precursor protein (APP), L1 cell adhesion molecule (L1CAM),
neural cell adhesion molecule 1 (NCAM-1), and other protein mediators of neurodevelopment
which normalize after initiation of PHH treatment [7]. Further, we have found that CSF APP lev-
els, and to a lesser extent NCAM-1 and L1CAM, correlate with ventricular size and possibly intra-
cranial pressure in PHH, responding in parallel with ventricular decompression [8]. With this
foundational work in PHH in mind, the primary objective of the current study was to characterize
the CSF levels of APP and related isoforms/cleaved products, L1CAM, NCAM-1, tau, phosphory-
lated tau (pTau), and aquaporin 4 (AQP4) in non-hemorrhagic, congenital hydrocephalus (CHC)
in order to investigate the possibility of a larger relationship between these CSF proteins and
hydrocephalus.
Materials and methods
Ethics statement
Approval from the Washington University (WU) Human Research Protection Office (#201203151,
201203126) was acquired prior to initiation of this study. Informed Consent (IC) procedures were
in accordance with the approved WU HRPO parameters. Written IC was obtained where possible;
however, verbal consent was permitted in cases where parents/guardians were unable to travel to
Washington University/St. Louis Children’s Hospital. In all cases, a log was kept with subject ID
and date and individual providing IC.
Research subjects
All patients18 years of age presenting to St. Louis Children’s Hospital/WU School of Medi-
cine for evaluation and/or surgical management of untreated, non-hemorrhagic CHC from
Cerebrospinal fluid biomarkers of congenital hydrocephalus
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2010–2014 were considered for recruitment. For inclusion, CHC subjects were required to have
ventriculomegaly on cranial imaging (frontal-occipital ratio (FOR)0.4) [9] and at least one of
the following: head circumference >98th percentile for corrected age; bulging fontanel or splay-
ing of the cranial sutures; papilledema; refractory headache, vomiting, or lethargy without other
identifiable cause; or upgaze paresis/palsy. Exclusion criteria included previous surgical treat-
ment for hydrocephalus; history of central nervous system infection or neoplasm; history of
open spina bifida; hydranencephaly; and PHH of prematurity. Subjects meeting inclusion/
exclusion criteria underwent surgical management of hydrocephalus following routine clinical
care pathways at St. Louis Children’s Hospital. For a detailed record of clinical, radiographic,
and neurosurgical parameters from the patients recruited for CHC, please refer to Table 1.
Cerebrospinal fluid samples
A Neonatal CSF Repository was established at WU in 2008 (WU Human Research Protection
Office #201101887 and #201203126). For the purposes of this study, CSF samples were acquired
Table 1. Clinical, radiographic, and neurosurgical parameters for the 20 congenital hydrocephalic CSF samples used throughout this study.
Race Sex Birthweight
(grams)
Birth
EGA
(weeks)
Age at
Sample
(months)
Aqueduct
Status
Associated Developmental
Brain MalformationBrain
Malformation?
Genetic
Studies
Genetic
Group
Assignment
Specific
Genetic
Anomaly
Surgery
Type
FOR
Caucasian F NA 27 5 Stenosis None CMA 1 N/A VPS 0.49
Caucasian M 3465 40 0 Stenosis None None 1 N/A VPS 0.59
Black M 3033 38 8 Patent DWV None 1 N/A VPS 0.77
Caucasian M 3200 41 0 Stenosis None None 1 N/A VPS 0.62
Asian M 3600 39 9 Patent None None 1 N/A VPS 0.55
Caucasian F 2500 40 11 Patent None None 1 N/A VPS 0.55
Caucasian F 2948 39 4 Stenosis None None 1 N/A VPS 0.58
Caucasian M 3095 37 0 Stenosis pACC CMA;
L1CAM
2, 3 G847X
(L1CAM)
VPS 0.89
Caucasian M 2820 38 1 Stenosis MCD, meningocele CMA 2, 3 1q25.2 VPS 0.61
Caucasian M 710 31 1 Stenosis None CMA 2 11q24.2 VSGS 0.48
Caucasian M 4040 36 0 Stenosis Rhombencephalosynapsis,
MCD, pACC, cerebellar
tonsillar ectopia
CMA 3 N/A VPS 0.78
Caucasian F 3300 34 0 Stenosis MCD, syntelencephaly,
cerebellar tonsillar ectopia
CMA 3 N/A VPS 0.79
Caucasian F 2115 33 13 Patent None None 3 N/A VPS 0.42
Caucasian M 3900 40 0 Stenosis None None 3 N/A VPS 0.57
Caucasian F 4180 39 0 Stenosis Open lip schizencephaly
versus in utero infarct
CMA 3 N/A VPS 0.83
Caucasian F 3345 36 147 Stenosis None None 3 N/A ETV 0.45
Caucasian M 2800 37 29 Patent None None 3 N/A VPS 0.49
Other F 3970 38 0 Stenosis None CMA 3 N/A VPS 0.63
Caucasian M 3350 39 0 Stenosis None CMA 3 N/A VPS 0.6
Black M 4337 39 4 Stenosis Hypoplastic cerebellum,
focal periventricular cystic
dilation
CMA 3 N/A VPS 0.72
Genetic group assignment categories: 1 = CHC with no known associations; 2 = CHC with known genetic alteration; 3 = CHC with developmental anomaly
involving the CNS or non-CNS organ systems.
AS: aqueductal stenosis; CMA: chromosomal microarray; CNS: central nervous systems; DWV: Dandy Walker Variant; ETV: endoscopic third
ventriculostomy; MCD: malformation of cortical development; pACC: partial agenesis of the corpus callosum; VPS: ventriculoperitoneal shunt; VSGS:
ventriculosubgaleal shunt.
doi:10.1371/journal.pone.0172353.t001
Cerebrospinal fluid biomarkers of congenital hydrocephalus
PLOS ONE | DOI:10.1371/journal.pone.0172353 February 17, 2017 3 / 20
at the time of initial CHC treatment. This study was initiated before the introduction of endo-
scopic third ventriculostomy (ETV) at our institution; thus, 18 subjects underwent placement of
ventriculoperitoneal shunts while one patient had an ETV. One other CSF sample was acquired
from a patient born at 31 weeks estimated gestational age who underwent initial ventriculosub-
galeal shunting. In all cases, once CSF was acquired, the sample was immediately transported
on ice from the operating room to the WU Neonatal CSF Repository, where it was centrifuged
at 2500 rpm for 6 minutes, and the supernatant was aliquoted into microcentrifuge tubes (500μl
each) and stored at -80˚C until experimental analysis. For comparative analysis, age matched
control CSF samples were obtained from patients18 years of age without known neurological
disease (corroborated on neuro-imaging) undergoing lumbar puncture for evaluation for infec-
tion, where cytological and microbiological (and in some cases PCR) evaluation of the CSF was
negative. Age matched lumbar CSF from infants and children with seizures or stroke, termed
other neurological diseases (OND), was also analyzed for an additional comparator group.
Measurement of candidate biomarkers
As described previously, enzyme-linked immunosorbent assays (ELISAs) were used to mea-
sure the CSF levels of each protein [7, 8]. The following commercially available ELISA kits
were used: APP (R&D Systems, Minneapolis, MN; catalog #DY-850); soluble APPα (sAPPα)
and soluble APPβ (sAPPβ) (IBL-International, Hamburg, Germany; catalog #27734 and
27732, respectively); amyloid-β42 (Aβ42), tau, and pTau (Fujirebio, Ghent, Belgium, catalog
#80177, 80226, 80062, respectively); NCAM-1 (R&D Systems; Minneapolis, MN; catalog #DY-
2408); L1CAM (DRG, Mountainside, NJ; catalog #EIA5074); AQP4 (USCN, Houston, TX, cat-
alog #SEA582Hu). Each CSF sample was run in duplicate for each ELISA, and the 96-well
plates were read at 450nm on a Versamax microplate reader (Molecular Devices, Sunnyvale,
CA). The Pierce Bicinchoninic Acid protein assay kit (Thermo Scientific, Waltham, MA) was
used to estimate the concentration of total protein (TP) in each CSF sample as previously
described [8]). Where noted, the CSF levels of each specific protein analyzed (APP, Aβ42,
sAPPα, sAPPβ, L1CAM, NCAM-1, tau, pTau, and AQP4) were normalized by total CSF pro-
tein to account for any non-specific changes in total CSF protein.
Statistical analysis
Data were expressed using mean ± standard deviation. Associations between continuous fac-
tors were assessed using the Pearson correlation coefficient. Simple logistic regression was
used to estimate predictive models of CHC with biomarkers. ANOVA with paired contrasts
was used to compare means across groups. Odds ratio (OR), sensitivity, and specificity were
calculated for candidate cut-points of normalized CSF proteins for predicting CHC. All data
analyses were performed using SAS1 9.3.
Results
Characteristics of study subjects
Data from 20 patients with untreated CHC were analyzed for this study (Table 1). Fifteen sub-
jects had MRI evidence of aqueductal stenosis (AS); the remaining 5 subjects demonstrated
patency of the cerebral aqueduct on MRI imaging. None had imaging findings suggestive of
4th ventricular outlet obstruction. Seven subjects had radiologic evidence of associated devel-
opmental brain malformations (Table 1). Six subjects had comorbid craniofacial anomalies,
six had developmental cardiopulmonary anomalies, and five subjects had comorbid genitouri-
nary anomalies. Ten subjects had chromosomal microarrays (CMAs) or targeted gene testing,
Cerebrospinal fluid biomarkers of congenital hydrocephalus
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3 of which subjects had identifiable genetic alterations (Table 1). The one subject with an
L1CAM mutation (G847X) was excluded from the L1CAM CSF biomarker analysis.
CSF total protein and ventricular size
There was a positive correlation of CSF TP levels with ventricular size in CHC (n = 20, r = 0.613,
p = 0.004) and in controls (n = 51, r = 0.48, p = 0.021) (Fig 1A and S1 Table). While CSF TP lev-
els appeared to decrease with subject age, the association was not significant in CHC (n = 20, r =
-0.252, p = 0.2847) but was significant in controls (n = 51, r = -0.43, p = 0.0017; Fig 1B and S2
Table). Interestingly, mean CSF TP levels were similar in control (356.55±277.6) and CHC
groups (512.38±450.22) (p = 0.65) but higher among subjects with OND than among control
and CHC subjects (p< 0.0001) (Fig 1C and Table 2).
Candidate CSF biomarkers of congenital hydrocephalus
CSF levels of APP, sAPPα, sAPPβ, Aβ42, tau, pTau, L1CAM, and NCAM-1 but not AQP4 or
TP were elevated in untreated CHC compared with age-matched controls or individuals with
OND (Table 2). In order to account for any potential influence of TP on specific biomarker
levels, each biomarker was normalized by CSF TP. With the exception of NCAM-1, CHC-
associated elevations in biomarkers persisted after normalizing each CSF biomarker by TP
(Table 2, Fig 2). Unless otherwise noted, CSF protein levels (APP, Aβ42, sAPPα, sAPPβ,
L1CAM, NCAM-1, tau, and pTau) are reported throughout the remainder of this study as nor-
malized by TP. With respect to ventricular size, normalized CSF tau levels were associated
with FOR in control subjects only (R = 0.52; p = 0.038) while normalized CSF L1CAM demon-
strated association with FOR in CHC subjects only (R = 0.55; p = 0.014) (S1 Table).
Age-dependence of CSF biomarkers of congenital hydrocephalus
Analysis of normalized CSF levels of APP, Aβ42, sAPPα, sAPPβ, L1CAM, NCAM-1, tau, and
pTau across the entire cohort of CHC subjects, ranging in age between 0 and 215 months,
demonstrated significant increases in CSF APP, Aβ42, sAPPα, sAPPβ, L1CAM, tau, and pTau
in CHC compared with control and OND subjects (Fig 2, Table 2). Normalized CSF tau levels
were associated with subject age alone in control subjects (R = -0.44; p = 0.009), while no other
biomarkers were associated with age in control or CHC subjects (S2 Table). However, the
Fig 1. Relationship of CSF total protein with ventricular size, subject age, and subject grouping. A. Association of CSF total protein (TP) with
ventricular size, estimated with frontal-occipital horn ratio (FOR) for control and congenital hydrocephalus (CHC) subjects. B. Association of TP with age for
control and CHC subjects. C. Comparison of TP among control, CHC, and other neurological disorders (OND) groups. Note the positive correlation of TP
with ventricular size (A) and the higher levels of TP in OND compared with control and CHC cases. *Denotes significance at p<0.05.
doi:10.1371/journal.pone.0172353.g001
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observed differences in normalized CSF biomarker levels, including APP, Aβ42, sAPPα,
sAPPβ, L1CAM, tau, and pTau, were greatest between CHC and control in subjects12
months of age (Figs 3 and 4). Beyond 12 months, the separation became inconsistent. Given
the complex relationship between CSF biomarkers and age, the remaining analyses in this
study focus on CHC in infants12 months of age.
Predictive ability of CSF biomarkers of congenital hydrocephalus in
infants12 months of age
Higher CSF levels of APP, Aβ42, sAPPα, sAPPβ, L1CAM, tau, and pTau corresponded to
greater incidence of CHC compared with control subjects and subjects with OND (Table 3,
Figs 3–5). Among the specific CSF proteins examined, normalized sAPPα had the strongest
predictive ability for CHC versus control (Table 4 and Fig 6, p<0.0001, area under the curve
(AUC) = 0.99). When data from OND subjects were included, sAPPα remained effective in
predicting CHC. Though not as strong, normalized sAPPβ, tau, APP, and L1CAM were also
predictive for CHC over control and OND subjects (Table 4 and Fig 6). CSF TP alone showed
no predictive ability for CHC (OR: 1.00, AUC: 0.61; Table 4 and Fig 6).
Among subjects12 months old in the CHC, control, and OND groups, a normalized
sAPPα cut-point of 0.407 provided the best prediction of CHC (OR = 528, Sensitivity = 0.941,
Specificity = 0.971, Table 4). Infants with sAPPα> 0.407 had 32 times greater risk (95% CI:
4.6–221) of having CHC than those with values below this cut-point. With a cut point of 2.43,
normalized sAPPβ had a strong predictive association of CHC (OR = 255, Sensitivity = 0.88,
Specificity = 0.97, Table 4) and infants above this cut point were almost 17 times more likely to
have CHC. Normalized tau also demonstrated a high predictive value for CHC with a cut
point of 0.0076 (OR = 171, Sensitivity = 0.941, Specificity = 0.914, Table 4). Infants with n-tau
Table 2. Cerebrospinal fluid levels of candidate biomarkers of congenital hydrocephalus. Mean ± SD CSF levels of candidate biomarkers of congeni-
tal hydrocephalus (both absolute and normalized by total protein) for control, congenital hydrocephalus (CHC), and other neurological disease (OND) groups,
along with the p-value for the ANOVA with paired contrasts comparison among the groups.
Control CHC OND CHC—Control p-value CHC—OND p-value OND—Control p-value
TP (ug/ml) 356.55±277.6 512.4±450.2 2818±3113 0.6449 <0.0001 <0.0001
APP (ng/ml) 340.9±188.64 1117±957.1 328.3±166.52 <0.0001 <0.0001 0.9318
Normalized APP 1.31±0.93 2.59±1.64 0.3061±0.33 <0.0001 <0.0001 0.0027
Abeta42 (ng/ml) 0.461±0.37 1.101±0.79 0.430±0.59 <0.0001 0.0006 0.8479
Normalized Abeta42 0.0015±0.001 0.0031±0.0022 0.00065±0.0013 <0.0001 <0.0001 0.0705
sAPPα (ng/ml) 114.95±97.83 701.1±768.9 77.5±54.43 0.0001 0.0017 0.8376
Normalized sAPPα 0.26±0.218 1.19±0.878 0.077±0.123 <0.0001 <0.0001 0.4042
sAPPβ (ng/ml) 325.1±281.34 3703±3304 250.3±187.25 <0.0001 <0.0001 0.9226
Normalized sAPPβ 0.826±0.798 8.741±11.13 0.257±0.395 0.0002 0.0026 0.8260
L1CAM (ng/ml) 19.57±20.35 182.7±239.0 10.28±16.39 <0.0001 0.0001 0.8017
Normalized L1CAM 0.055±0.054 0.282±0.23 0.01118±0.023 <0.0001 <0.0001 0.2543
NCAM-1 (ng/ml) 161.3±92.31 266.7±220.9 155.9±119.66 0.0048 0.0232 0.8971
Normalized NCAM-1 0.657±0.558 0.626±0.511 0.1594±0.217 0.8133 0.0100 0.0017
Tau (ng/ml) 2.081±2.813 10.33±7.607 4.632±8.255 <0.0001 0.0138 0.2277
Normalized Tau 0.0038±0.0033 0.0319±0.0368 0.0044±0.0118 <0.0001 0.0020 0.9362
pTau (ng/ml) 0.76±0.926 1.97±2.137 0.3553±0.303 0.0040 0.0060 0.4518
Normalized pTau 0.0014±0.0012 0.0044±0.0042 0.0002323±0.0004 0.0002 <0.0001 0.2024
AQP4 (ng/ml) 0.5436±0.566 1.126±1.845 0.3146±0.3062 0.1867 0.1383 0.6407
Normalized AQP4 0.0016±0.0015 0.0024±0.0037 0.00032±0.00053 0.3811 0.0742 0.2245
doi:10.1371/journal.pone.0172353.t002
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values above 0.0076 were at 28 times more likely to have CHC. Normalized L1CAM levels
showed predictive ability, albeit somewhat less robust (OR = 56, Sensitivity = 0.88, Specific-
ity = 0.89), with levels above the cut point of 0.095 associated with 13 times greater risk of
CHC.
Congenital hydrocephalus subgroup analyses
In order to further characterize CSF biomarker increases within CHC, subjects were analyzed
for aqueduct of Sylvius status (AS or patent), the presence of developmental brain anomalies,
or a known genetic alteration. No differences were seen among the three groups with respect
to FOR or TP, and none of the CSF biomarkers demonstrated significant differences among
groups (Table 5).
Discussion
In the current study, levels of APP, sAPPα, sAPPβ, Aβ42, tau, pTau, L1CAM, NCAM-1, AQP4,
and total protein were investigated in the CSF of children with and without congenital hydro-
cephalus. Of these candidate CSF biomarkers, all but CSF TP, AQP4, and NCAM-1 showed a
robust association with CHC. Normalized sAPPα demonstrated a particularly strong relation-
ship with infantile CHC, with high sensitivity and specificity. Soluble APPβ, tau, APP, and
L1CAM were also able to discriminate CHC, though not as strongly as sAPPα. While CSF TP
showed an association with ventricular size in controls and CHC, it did not exhibit predictive
ability for CHC.
The pathophysiology of hydrocephalus is multifactorial with a pervasive impact on the brain.
Previous studies of CSF composition in hydrocephalus (reviewed in [10–16] have suggested
that periventricular axonal damage and demyelination [13, 17, 18], apoptosis [19], disruption of
the blood-brain barrier [20], reduced cerebral blood flow accompanied by hypoxia and ischemia
[14], altered metabolism [21], reductions in neurotransmitters and neuromodulators [18, 22–
24], and neuroinflammation [13, 25–31] may all play important roles in the progression of
hydrocephalus. Older studies of various biomarkers associated with these mechanisms in devel-
oping brains have suggested that none were robust enough to predict clinical outcome [10, 32],
Fig 2. CSF biomarker levels in control, congenital hydrocephalus, and other neurological diseases. Box and whisker plots comparing normalized
levels of CSF biomarkers measured in control, other neurological diseases (OND), and congenital hydrocephalus (CHC) subjects across all ages. Note
the significant (*, p<0.05) increases in APP, Aβ42, sAPPα, sAPPβ, L1CAM, NCAM-1, tau, and pTau in CHC compared to both control and OND cases.
doi:10.1371/journal.pone.0172353.g002
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but more recent reports, especially those on adult and aging patients with idiopathic normal
pressure hydrocephalus (iNPH), indicate that CSF levels of Aβ42 and tau, correlate well with
clinical signs and symptoms [11, 12, 15, 18, 32–39]. Since APP must be delivered to synaptic
membranes via axonal transport for cleavage into various isoforms [40, 41], and because peri-
ventricular white matter almost always exhibits impaired axonal transport and cytopathology
during ventriculomegaly [2], it is understandable that CSF APP could originate from white mat-
ter axons and their terminal synapses. Experimental studies have shown that axoplasmic trans-
port is impaired in hydrocephalus [42], synaptogenesis is modulated by APP[43, 44], and APP
serves as a neurodevelopmental trophic factor [43]. Further, the processing of APP is highly reg-
ulated at multiple levels, and alterations in these pathways are etiologic in pathological condi-
tions [45]. For example, cleavage of APP by α-secretase (e.g. ADAM10) releases sAPPα, whereas
cleavage by the β-secretase β–site APP-cleaving enzyme (BACE-1) elaborates sAPPβ, yet only
the latter is believed to be amyloidogenic. Any CHC-associated alteration of such balance could
thus result in differential abundance of these isoforms in the CSF. The microtubule-associated
protein tau stabilizes the axonal cytoskeleton [46]. Finally, the neuroepithelial cells of the ventric-
ular zone and the ependymal lining of the ventricular wall rely on cell adhesion molecules such
as L1CAM and NCAM for structural integrity, and ventricular zone junctional proteins are
Fig 3. Relationship of CSF biomarker levels to congenital hydrocephalus and age at CSF sample. Regression analysis of normalized CSF APP,
Aβ42, sAPPα, sAPPβ levels and age at sample (in months) in congenital hydrocephalus (CHC, shown in red) and non-CHC groups (control and other
neurological diseases subjects, shown in blue). In general, APP, Aβ42, sAPPα, and sAPPβ levels were most different between CHC and control subjects
<12 months of age.
doi:10.1371/journal.pone.0172353.g003
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known to be impaired in hydrocephalus [47–49]. Therefore, while reduced CSF flow and protein
flux in hydrocephalus could be responsible for our findings (discussed below), it is also possible
that the changes we have observed in CSF biomarkers reflect pathological alterations in periven-
tricular tissue as much as changes in CSF flow.
The CSF biomarkers selected for study in the current report have been previously examined
in PHH of prematurity [7, 8] and represent a natural starting point for targeted investigation
of CSF biomarkers in CHC. However, CSF alterations in CHC may vary significantly from
other etiologies of hydrocephalus, including hemorrhagic, infectious, or other causes. Indeed,
the classification of CHC itself may include a range of etiologies for hydrocephalus, each with
different biological underpinnings. Seminal research studies reported over the last several
years have implicated alterations in cell junction pathology [4, 48], precursor cell migration
[49], ependymal polarity and cilia [50–53], and other mechanisms in the pathogenesis of
hydrocephalus (reviewed in [1] and [6]). In a related project, we have used CSF proteomics to
conduct a higher-level survey of pathophysiology at play in CHC; results from that effort are
forthcoming.
Fig 4. Relationship of CSF biomarker levels to congenital hydrocephalus and age at CSF sample. Regression analysis of normalized CSF L1CAM,
NCAM-1, tau, and phosphorylated tau (pTau) levels and age at sample (in months) in congenital hydrocephalus (CHC, shown in red) and non-CHC groups
(control and other neurological diseases subjects, shown in blue). Note that these proteins exhibited a similar pattern as APP and its isoforms by being most
different in CHC <12 months of age.
doi:10.1371/journal.pone.0172353.g004
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Novel biomarkers of CHC and other forms of hydrocephalus are urgently needed to
improve the clinical care and treatment of children affected by these conditions. At present, a
diagnosis of hydrocephalus is usually made based on symptoms (e.g. irritability, nausea/vomit-
ing, or headaches in a child able to convey symptoms), signs (e.g. tense fontanel, macroce-
phaly, papilledema, cranial nerve deficits), and ventricular enlargement on neuro-imaging.
However, the symptoms and signs used in the diagnosis of hydrocephalus are nonspecific, and
ventricular size may be affected by a number of conditions common to infants and children at
risk for hydrocephalus, including brain malformations, intracranial hemorrhage, and hypoxia/
ischemia. Clinically, the diagnosis of hydrocephalus and the optimal timing of initiation of
treatment (CSF shunting or ETV) are often unclear. Once implemented, treatment is invari-
ably challenging to assess, since imaging is frequently unreliable after shunting, and few other
tools are available to provide insight into CSF shunt or ETV function or, importantly, optimiz-
ing the child’s neurodevelopmental trajectory.
While the most direct effect of these novel CSF biomarkers for CHC may be their diagnostic
and therapeutic potential, the results reported herein also open new lines of scientific inquiry
into the pathogenesis and pathophysiology of CHC. Elevations in CSF biomarkers, APP and
tau in particular, may suggest recent or ongoing neurological injury, for example axonal
stretch-related injury or synaptic disruption, as has been proposed in traumatic brain injury
and other conditions (reviewed in [54]). In particular, Del Bigio and colleagues have repeatedly
stressed the importance of periventricular white matter injury as a major factor in the patho-
physiology of hydrocephalus [2, 55, 56]. Further, differential regulation of APP processing and
amyloid isoforms may provide insight into specific pathways involved in the pathogenesis of
hydrocephalus and its neurological sequelae and/or the repair mechanisms at play in neuro-
logical recovery. The finding of early elevations, but later normalization, of APP and other
CSF biomarkers is in agreement with the notion of acute and chronic stages of hydrocephalus
Table 3. Cerebrospinal fluid levels of candidate biomarkers of congenital hydrocephalus in infants12 months of age. Mean ± SD CSF levels of
candidate biomarkers of congenital hydrocephalus (both absolute and normalized by total protein) for CSF samples12 months of age, for control, congenital
hydrocephalus (CHC), and other neurological disease (OND) groups, along with the p-value for the ANOVA with paired contrast comparison among groups.
Control CHC OND CHC—Control p-value CHC—OND p-value OND—Control p-value
TP (ug/ml) 506.2±306.4 562.9±469.4 3597±3673 0.9039 <0.0001 <0.0001
APP (ng/ml) 409.7±197.55 1276±953.44 348.9±135.09 <0.0001 0.0002 0.7795
Normalized APP 1.05±0.658 2.834±1.64 0.257±0.273 <0.0001 <0.0001 0.0552
Abeta42 (ng/ml) 0.6747±0.389 1.232±0.789 0.5653±0.716 0.0047 0.0100 0.6415
Normalized Abeta42 0.00159±0.0011 0.0033±0.0024 0.0007±0.0014 0.0016 0.0003 0.1578
sAPPα (ng/ml) 113.26±99.46 819.00±776.85 77.49±54.43 <0.0001 0.0002 0.8404
Normalized sAPPα 0.2227±0.132 1.365±0.827 0.077±0.123 <0.0001 <0.0001 0.4477
sAPPβ (ng/ml) 319.6±285.41 4348±3165.18 250.3±187.25 <0.0001 <0.0001 0.9221
Normalized sAPPβ 0.7288±0.629 10.24±11.45 0.257±0.395 <0.0001 0.0006 0.8533
L1CAM (ng/ml) 25.85±22.70 216.6±246.57 15.6±18.63 <0.0001 0.0010 0.8473
Normalized L1CAM 0.0544±0.051 0.3327±0.219 0.015±0.0278 <0.0001 <0.0001 0.4275
NCAM-1 (ng/ml) 171.1±63.28 307±215.27 195.7±126.05 0.0032 0.0608 0.6524
Normalized NCAM-1 0.4572±0.337 0.705±0.514 0.1598±0.225 0.0478 0.0014 0.0547
Tau (ng/ml) 2.70±3.035 10.84±7.552 4.632±8.255 <0.0001 0.0134 0.3988
Normalized Tau 0.00455±0.0036 0.0272±0.0228 0.0044±0.0118 <0.0001 0.0003 0.9849
pTau (ng/ml) 0.8747±0.9711 2.196±2.2356 0.355±0.303 0.0055 0.0036 0.3618
Normalized pTau 0.0015±0.0013 0.0042±0.0037 0.00026±0.0004 0.0005 0.0001 0.1757
AQP4 (ng/ml) 0.5436±0.5661 1.126±1.844 0.3146±0.3062 0.1867 0.1383 0.6407
Normalized AQP4 0.0016±0.0015 0.0024±0.0037 0.0003±0.0005 0.3811 0.0742 0.2245
doi:10.1371/journal.pone.0172353.t003
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advanced by McAllister [6] and others[57, 58]. Experimental models have demonstrated an
acute phase to hydrocephalus, in which there occurs an active pathophysiological insult and
ensuing inflammation as well as a chronic phase in which ventriculomegaly stabilizes, the
Fig 5. Logistic probability of CSF biomarkers for congenital hydrocephalus. Shown are logistic probability curves of normalized CSF levels of APP,
sAPPα, sAPPβ, tau for congenital hydrocephalus (CHC) or no CHC (control and other neurological diseases subjects). Note that sAPPα, followed by
sAPPβ, had the highest predictive ability for differentiating CHC.
doi:10.1371/journal.pone.0172353.g005
Table 4. Evaluation of the predictive relationship between CSF biomarkers and congenital hydrocephalus. Logistic regression parameters for nor-
malized levels of all potential biomarkers measured in this study are shown. The strongest predictors of CHC were normalized levels of sAPPα, sAPPβ, and
Tau using cut points of 0.407, 2.43, and 0.0076 respectively. The weakest predictors of CHC were normalized pTau and NCAM-1. ROC AUC: receiver operat-
ing characteristics area under the curve; CI: confidence interval; Bonferroni corrected threshold (0.0055).
Normalized
APP
Normalized
Aβ42
Normalized
sAPPα
Normalized
sAPPβ
Normalized
L1CAM
Normalized Tau Normalized
pTau
Total
Protein
p-value <0.0001 0.0003 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.1069
ROC AUC 0.931 0.805 0.986 0.948 0.913 0.945 0.850 0.612
Cut Point 1.334 0.0015 0.407 2.43 0.095 0.0076 0.0021 900.0
Odds Ratio (95%
CI)
31.07 5.72–
168.5
34.91 4.10–
297.49
528.0 30.99–
8995.5
255.00 21.44–
3033.3
56.00 9.17–
342.13
170.67 16.42–
1774.19
22.56 4.91–
103.71
1.0833
0.28–4.18
Relative Risk
(95% CI)5% CI)
10.57 2.68–
41.61
14.81 2.12–
103.68
32.00 4.62–
221.48
16.87 4.36–
65.28
13.22 3.37–
51.88
27.79 3.99–
193.35
7.47 2.45–
22.77
1.06 0.42–
2.68
Sensitivity 0.8824 0.9412 0.9412 0.8824 0.8750 0.9412 0.8235 0.7647
Specificity 0.8056 0.6857 0.9706 0.9714 0.8889 0.9143 0.8286 0.2500
doi:10.1371/journal.pone.0172353.t004
Cerebrospinal fluid biomarkers of congenital hydrocephalus
PLOS ONE | DOI:10.1371/journal.pone.0172353 February 17, 2017 11 / 20
changes noted in the acute phase subside, and perhaps compensatory mechanisms become
involved [57–59].
Fig 6. Receiver operating characteristic curves for CSF biomarkers of congenital hydrocephalus. Receiver operating characteristic (ROC) curves
for normalized levels of APP, sAPPα, sAPPβ, tau, and CSF total protein (TP) in infants 12 months. Normalized sAPPα had the strongest predictive ability
for congenital hydrocephalus (CHC), followed by normalized sAPPβ and tau; CSF TP alone showed no predictive ability for CHC (see also Table 4).
doi:10.1371/journal.pone.0172353.g006
Table 5. Mean ± SD CSF levels of candidate biomarkers of CHC for CSF samples12 months of age, for samples that showed aqueductal steno-
sis, CHC with developmental anomalies, or CHC with a known genetic alteration. All values shown are the normalized levels of proteins.
CHC + Aqueduct
Stenosis
CHC–Aqueduct
Stenosis
CHC + Developmental Brain
Malformation
CHC without Brain
Malformation
CHC + Genetic
Alteration
CHC–Genetic
Alteration
FOR 0.642±0.132 0.604±0.101 0.648±0.154 0.600±0.106 0.660±0.209 0.606±0.121
TP (ug/
ml)
608.1±480.0 339.6±305.5 627.0±519.8 443.8±382.7 929.1±603.4 455.2±380.7
APP 2.903±1.77 2.416±1.502 2.560±1.775 2.634±1.590 1.908±0.747 2.621±1.678
Abeta42 0.003±0.002 0.004±0.002 0.003±0.002 0.004±0.002 0.002±0.002 0.003±0.002
sAPPα 1.462±0.843 0.896±0.743 1.088±0.710 1.219+0.908 1.193±0.432 1.182±0.902
sAPPβ 11.25±11.84 3.62±2.89 8.066±10.91 8.569±9.70 10.97±4.28 8.95±11.39
L1CAM 0.371±0.207 0.232±0.225 0.325±0.237 0.257±0.198 0.375±0.189 0.282±0.233
NCAM-1 0.713±0.564 0.512±0.272 0.585±0.598 0.5678±0.320 0.431±0.155 0.636±0.523
Tau 0.027±0.024 0.039±0.046 0.032±0.043 0.035±0.042 0.015±0.002 0.033±0.038
pTau 0.005±0.004 0.005±0.006 0.005±0.004 0.005±0.005 0.006±0.004 0.004±0.004
AQP4 0.003±0.004 0.001±0.0005 0.003±0.004 0.001±0.0004 0.002±0.002 0.002±0.004
doi:10.1371/journal.pone.0172353.t005
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The relationships between increased CSF proteins and CSF physiology is likely to be com-
plex. From a traditional perspective, obstructions that decrease CSF flow and/or absorption
would be expected to impair clearance and cause CSF protein concentrations to rise. Fifteen of
20 of our patients exhibited aqueductal stenosis, potentially implicating CSF stasis in high TP
and biomarker levels (though our limited analysis of 15 subjects with aqueductal stenosis ver-
sus 5 with patent aqueducts suggested no difference in TP or biomarker levels). In addition, an
increase in total protein could have impacted CSF-parenchymal osmotic gradients and pro-
moted ventriculomegaly in the same way that and dextrose- or sucrose-induced gradients
cause mild-moderate ventriculomegaly in adult rats, dogs and cats [60–62]. Furthermore, clin-
ical studies have shown that levels of surfactant proteins, specifically types A and C, increase
significantly in hydrocephalus with and without aqueductal stenosis [63]. Surfactant protein A
is associated with the blood-brain and blood-CSF barriers, while surfactant protein C is located
in choroid plexus epithelial cells and ependyma. Thus, it is conceivable that CSF protein eleva-
tions, initially caused by periventricular tissue damage and/or CSF stasis, could exacerbate
ventriculomegaly by impeding CSF flow and absorption as well as by drawing interstitial fluid
from the parenchyma into the ventricles.
High CSF protein concentrations also could be related to alterations in the CSF glymphatic
system (reviewed in Iliff et al [64–66]). This recently-described system helps mediate CSF
absorption via paravascular pathways associated with both penetrating arterioles and micro-
vessels within the cortical parenchyma. Impairment of these pathways during traumatic brain
injury increases CSF levels of tau and this effect is exacerbated in mice lacking aquaporin-4
channels [67, 68]. Likewise, clearance of soluble amyloid-beta and intraventricular adeno-asso-
ciated viruses is reduced in these knockout mice[69, 70]. While this mechanism of CSF absorp-
tion has not been well-studied in immature brains, aged rats with amyloid-beta injected into
cortical parenchyma show diminished glymphatic/paravascular clearance[71]. Since aqua-
porin-4 channels are closely associated with the glymphatic system, it is worth noting that CSF
aquaporin-4 levels were not changed in this limited study, making the role of glymphatic dis-
turbance less certain.
In addition to PHH, many of the CSF biomarkers examined in the current report have been
investigated in the setting of Alzheimer’s disease, Parkinson’s disease, and notably, iNPH,
among other conditions (reviewed in[72]). For example, sAPPα and sAPPβ, but not tau and
pTau, may also be useful in distinguishing iNPH from Alzheimer’s disease or possibly other
conditions that affect this older population[33, 73–76]. Interestingly, we found previously that
CSF sAPPα was an excellent predictor of PHH, though the sAPPα levels that we observed in
PHH (lumbar CSF: mean 1667±1227 ng/ml, ventricular CSF mean 932.9±781.51 ng/ml) and
in CHC in the current report (ventricular CSF, mean 701.1±768.9), are considerably higher
than those described by Miyajima et al. for lumbar samples from patients with iNPH (152
±60ng/ml), which were in their work decreased from levels in controls and Alzheimer’s
patients. These differences may suggest very different pathophysiological processes in PHH,
CHC, and iNPH but certainly suggest involvement of APP processing pathways in the patho-
genesis of hydrocephalus more broadly.
A number of limitations must be acknowledged in this research project. While, to our
knowledge, this study represents the largest study of CSF in non-hemorrhagic CHC, it none-
theless details an investigation of a modest sample size from a heterogeneous group of patients
with likely myriad etiologies for hydrocephalus. The samples themselves span a wide range of
ages with relatively fewer samples coming from individuals older than two years. Also contrib-
uting to the heterogeneity is the number and variability of associated brain abnormalities,
non-CNS conditions, and genetic findings in the study population. It is likely that as we learn
more about genetic alterations and their relationship to hydrocephalus that many of those
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individuals in this study in which no genetic etiology was identified will indeed have had a
genetic cause and we were simply not yet able to detect it. While narrowing the scope of the
project somewhat, subjects with hydrocephalus associated with myelomeningocele were delib-
erately excluded from the study, since factors such as active CSF leak or fluid shifts and uncer-
tainty of infection presented challenging confounds to the current analysis. An inevitable
limitation and challenge to studies of human CSF in children is the absence of true age-
matched control CSF samples; the current study relies on CSF samples from human infants
and children who underwent a lumbar puncture for clinical evaluation for sepsis or other diag-
nostic assessment where the CSF cultures and evaluation were negative. Ethical principles
clearly prohibit routine CSF collection from asymptomatic patients. Another limitation inher-
ent to this and similar studies is the potential for bias in cross-group comparisons introduced
by rostrocaudal protein gradients, since control and OND CSF samples were acquired via lum-
bar puncture and CHC samples were acquired by ventricular cannulation. Reiber et al have
demonstrated that different sources of CSF proteins exhibit different hydrodynamics, espe-
cially in relation to CSF flux variations associated with blood-brain and blood-CSF barriers
[77–80]. For example, CSF tau clearly originates from cortical axons and oligodendrocytes
even when measured in lumbar samples and is not dependent upon blood-CSF barrier dys-
function [81]. We recently addressed this bias in the setting of PHH of prematurity, where lum-
bar punctures are frequently performed early in the treatment of the condition, and CSF can be
conveniently compared between PHH, control, and OND [82]. In PHH, differences observed
in APP and derivative isoforms, L1CAM, and TP were found to be robust versus other condi-
tions, even when controlling for CSF access site. Lumbar punctures are not commonly per-
formed in infants and children with CHC, however, so a direct comparison is not possible. It is
worth noting that our samples were not affected by the use of ventricular catheters because they
were obtained prior to the initiation of surgical treatment. Likewise, intracranial pressure mea-
surements are not commonly obtained in CHC patients, since patients are under general anes-
thesia at the time of surgery, and numerous factors (e.g. anesthetic agent, respiratory rate/pCO2,
body position, fluid loss in dural opening or ventricular cannulation) impact intracranial pres-
sure under these conditions. The relationship between intracranial pressure and CSF biomark-
ers is of great interest, however, and our basic science efforts are directed at delineating this
relationship in an experimental model where such factors can be rigorously controlled.
Conclusions
CSF biomarkers including APP, sAPPα, sAPPβ, tau, and L1CAM hold promise as biomarkers
of CHC in infants and young children. Soluble APPα in particular demonstrated a strong rela-
tionship with infantile CHC, with high sensitivity and specificity. In addition to supporting
potential diagnostic and therapeutic roles for the care of children with CHC, the results of this
study provide insight into the pathophysiology of CHC during this critical period in
neurodevelopment.
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